Compare Sanofi SA (SNY) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Williams Companies Inc — how do they compare? Sanofi SA trades at $40.07 (market cap $95.18B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Sanofi SA and Williams Companies Inc are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Williams Companies Inc for 58 Days on average.
| SNY | WMB | |
|---|---|---|
Market Cap | $95.18B | $88.48B |
Volume | 2,995,646 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $52.34 | $79.40 |
52-Week Low | $39.51 | $56.51 |
Typical Hold Time | 94 Days | 58 Days |
Enterprise Value | $114.48B | $119.11B |
Dividend Yield | 6.01% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
WMB trades at $72.34, up 1.23% with a bullish technical signal. The company shows strong profitability with 25.18% net income margin and 24.02% ROE, though valuation ratios appear elevated with P/E of 28.82. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. Natural gas demand growth from AI data centers provides strategic positioning for future revenue growth.
WMB offers attractive dividend yield with 79% analyst buy ratings and $87.27 consensus target, suggesting 21% upside. Key risks include energy market volatility and high debt levels at $24.74 billion long-term debt. The stock presents opportunity for income investors seeking exposure to resilient midstream energy infrastructure with fee-based revenue model.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
